Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study

Acute graft versus host disease (aGVHD) remains a major problem after allogeneic hematopoietic stem cell transplantation. Standard frontline therapy for aGVHD involves corticosteroids. However, fewer than half of patients have a lasting complete response. The long-term mortality rate of steroid-refr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Yamin Tan, Haowen Xiao, Depei Wu, Yi Luo, Jianping Lan, Qifa Liu, Kang Yu, Jimin Shi, Jingsong He, Weiyan Zheng, Xiaoyu Lai, Yuanyuan Zhu, Kaili Du, Yishan Ye, Yanmin Zhao, Gaofeng Zheng, Yongxian Hu, Xiaoyan Han, Yanlong Zheng, Guoqing Wei, Zhen Cai, He Huang
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis Group 2017-03-01
Saila:OncoImmunology
Gaiak:
basiliximab
etanercept
hematopoietic stem cell transplantation
steroid-refractory acute gvhd
Sarrera elektronikoa:http://dx.doi.org/10.1080/2162402X.2016.1277307
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak